Europe stands at an inflection point in life‑sciences innovation. From radioligand therapies in oncology to cell, gene and RNA‑based platforms, such advances in biotechnologies are opening new possibilities to treat disease in ways that were unthinkable just a decade ago. European innovators are at the forefront of medical advancement with these technologies already reshaping clinical practice and offering new hope to patients with serious and often life‑threatening conditions.

But innovation in biotechnology does not always follow a simple or linear path, or sit neatly into existing regulations. They are increasingly complex, high‑risk and capital‑intensive during development; their production often requires advanced manufacturing capabilities, highly specialized clinical infrastructure and skills; and requires a regulatory environment that is conducive to next-generation technologies that are pushing the boundaries of possibility.

From scientific potential to patient impact

As technology platforms converge and evolve, innovation no longer fits neatly into traditional categories, posing both opportunity and risk for Europe as it competes globally to be the location for biotechnology growth.

While its scientific base remains strong, too often there is a gap between discovery and real‑world delivery. Fragmented processes, slow and inconsistent clinical trial approvals, and regulatory uncertainty are real risks that have potential to hold back Europe’s ability to translate innovation into patient benefit. Global companies make investment decisions based on where innovation is most likely to reach patients quickly and predictably.

The EU Biotech Act offers a timely opportunity to address this gap. If implemented with ambition, it can help ensure that Europe remains an attractive environment for research, clinical development and advanced manufacturing. Ultimately accelerating access to new therapies for patients.

Getting the foundations right

Three elements of the Biotech Act will be particularly decisive.

First, investment incentives matter. A  meaningful extension of the Supplementary Protection Certificate (SPC) for qualifying biotech and advanced therapies is not an abstract policy tool; it is a practical signal that can influence investment decisions. For complex technologies, biologics, cell and gene therapies, and other advanced platforms, longer development timelines and higher risk mean that predictability is essential.

Second, definitions must reflect how science actually evolves. Applying a consistent, future‑proof definition of biotechnology across the Act is critical to avoid unintentionally excluding emerging platforms. Narrow, process‑based definitions risk freezing policy in time, while innovation moves on. A broad,advanced technology definition could better support Europe’s diverse and fast‑growing biotech ecosystem.

Third, clinical trial reform is central to patient access. Faster, more predictable and harmonized trial approvals, including for radioligand therapies, directly influence where global development programs are run. Speed and consistency are not only pro-innovation measures; they are patient‑centered reforms that can shorten the time it takes for breakthrough therapies to reach those who need them.

An access moment

Radioligand therapy illustrates what is at stake. Europe pioneered this highly targeted approach to cancer treatment, but its delivery depends on more than scientific excellence. It requires aligned regulation, specialized diagnostics, secure supply chains and trained multidisciplinary teams. Where systems are ready, patients benefit sooner. Where readiness lags, access slows even when the science is proven.

This is why biotech policy cannot be separated from broader questions of system readiness and access. Europe does not lack ideas or ambition. The real test is whether policy choices create an environment where innovation can move from the lab to the clinic efficiently, predictably, and at scale.

The Biotech Act is a rare and ambitious opportunity to strengthen Europe’s life‑sciences industry while improving patient access to advanced therapies. By aligning incentives, definitions and clinical trial frameworks with the realities of modern biotechnology, Europe can bridge the gap between potential and impact.